Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
May 20 AZN Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20 AZN AstraZeneca, Amgen release mid-stage data on Tezspire for COPD
May 20 AZN AstraZeneca to build $1.5B ADC manufacturing plant in Singapore
May 20 AZN AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
May 20 OPK $3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
May 20 AZN Trending tickers: Gold, Ryanair, Nvidia and AstraZeneca
May 20 AZN AstraZeneca to build $1.5bn ADCs facility in Singapore
May 20 AZN Pfizer wins cancer drug patent case against AstraZeneca
May 20 AZN AstraZeneca Plans $1.5 Billion Manufacturing Facility In Singapore
May 19 AZN New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19 AZN Biopharma M&A surges year over year in Q1
May 17 AZN Puma Biotech pares gain amid Wyeth victory in Tagrisso patent case against AstraZeneca
May 17 AZN AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints
May 16 GTLS (GTLS) - Analyzing Chart Industries's Short Interest
May 16 AZN AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
May 16 AZN Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 AZN AstraZeneca COVID therapy succeeds in late-stage study for the vulnerable
May 16 AZN AstraZeneca selects new heart failure target with BenevolentAI
May 15 APGE Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 14 DVAX FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags